Merck (MRK) Ticks Higher Following Positive Odanacatib Phase III News
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $127.77 -1.87%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +3.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +3.8%
Join SI Premium – FREE
Merck & Co. (NYSE: MRK) shares are ticking higher in late trading Wednesday, following positive news for its investigational cathepsin K (cat-K) inhibitor, odanacatib.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) call put ratio 1.2 calls to 1 put into quarter results
- Altimmune starts Phase 3 trial of pemvidutide for MASH
- FDA grants orphan drug status to Zai Lab's zoci for neuroendocrine carcinomas
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
